Skip to main content
Clinical Trials/NCT05649904
NCT05649904
Recruiting
N/A

Use of Active Fluid Exchange to Therapeutically Treat Intracranial Bleeding and Infection

Ohio State University1 site in 1 country240 target enrollmentFebruary 7, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Intraventricular Hemorrhage
Sponsor
Ohio State University
Enrollment
240
Locations
1
Primary Endpoint
Rate of revision procedures for the IRRAflow and EVD/Drainage catheters
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD).

Subjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.

Registry
clinicaltrials.gov
Start Date
February 7, 2023
End Date
January 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Patrick Youssef

Clinical Assistant Professor of Neurological Surgery

Ohio State University

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years of age
  • Need of drainage for one of the following underlying conditions: Intraventricular hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis
  • Indication for active treatment evaluated by treating physician for underlying conditions; Intraventricular hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis
  • Signed informed consent obtained by subject or Legally Authorized Representative

Exclusion Criteria

  • Subject has fixed and dilated pupils
  • Pregnant women
  • Presence of Moyamoya
  • History or presence of clotting disorder.
  • Platelet count less than 100,000, INR greater than 1.4

Outcomes

Primary Outcomes

Rate of revision procedures for the IRRAflow and EVD/Drainage catheters

Time Frame: Immediately post-procedure

Secondary Outcomes

  • Indwell time of EVD/Drainage and IRRAflow Catheter(Immediately post-procedure)
  • Length of ICU stay(Baseline)
  • Rate of shunt dependency(Immediately post-procedure)
  • Time to clearance of blood or bacterial mass as measured by head CT scan(Immediately post-procedure)
  • Mortality rates - intraprocedural and at 30 days(30 days post subject discharge)
  • Functional Status - at inclusion and 30 days(30 days post subject discharge)
  • Rate of catheter-related infection(Immediately post-procedure)

Study Sites (1)

Loading locations...

Similar Trials